Skip to content
Catalyst

omeprazoleWhat was measured

Measured, with no finding

24 endpoints

Show what was measuredHide what was measured
  • gut microbiota alpha/beta diversity

    no effect

    No significant within-group changes over time or between-group differences or partitions at both V0 and V2 were evidenced by alpha or beta diversity analysis, respectively.

    PMID 37307528 · one of two readings recorded this

  • serum creatinine concentration

    no effect

    The serum creatinine concentration did not differ significantly after a year, after two and three years in group I and separately in group II (Tables 2 and 3) compared to the baseline values.

    PMID 39805983 · one of two readings recorded this

  • estimated glomerular filtration rate (CKD-EPI creatinine equation), percentage change from baseline after 3 years

    decreases, -5.56% (omeprazole plus tacrolimus group) vs 9.13% (famotidine plus tacrolimus group), p = 0.0343, p = 0.0343

    Not recorded as a finding: the comparison was against another active treatment

    However, there was a significant difference between percentage variation of GFR after 3 years of the study (− 5.56% (− 17.24 to 0.00%) vs 9.13% (4.49 to 16.62%), p = 0.0343) (Table 4).

    PMID 39805983 · one of two readings recorded this

  • estimated glomerular filtration rate (CKD-EPI), percentage change from baseline at 3 years

    decreases, -5.56% (omeprazole group) vs 9.13% (famotidine group), p = 0.0343, p = 0.0343

    However, there was a significant difference between percentage variation of GFR after 3 years of the study (− 5.56% (− 17.24 to 0.00%) vs 9.13% (4.49 to 16.62%), p = 0.0343) (Table 4).

    PMID 39805983 · one of two readings recorded this

  • percentage change in eGFR (CKD-EPI) at 3 years, omeprazole group vs famotidine group

    -5.56% (Group I, omeprazole) vs 9.13% (Group II, famotidine), p = 0.0343, p = 0.0343, n = 18

    Not recorded as a finding: Comparator is famotidine, an active agent, not absence of omeprazole -- no placebo or no-drug arm exists for this between-group contrast, so it cannot become an outcome edge even though a node (egfr) exists.

    However, there was a significant difference between percentage variation of GFR after 3 years of the study (− 5.56% (− 17.24 to 0.00%) vs 9.13% (4.49 to 16.62%), p = 0.0343) (Table 4).

    PMID 39805983 · one of two readings recorded this

  • percentage change in eGFR (CKD-EPI) at 3 years, omeprazole vs famotidine

    -5.56% (Group I, omeprazole) vs 9.13% (Group II, famotidine), p = 0.0343, p = 0.0343, n = 18

    However, there was a significant difference between percentage variation of GFR after 3 years of the study (− 5.56% (− 17.24 to 0.00%) vs 9.13% (4.49 to 16.62%), p = 0.0343) (Table 4).

    PMID 39805983 · one of two readings recorded this

  • serum creatinine concentration, percentage change from baseline at 3 years

    no effect, 4.05% (omeprazole) vs -8.08% (famotidine), p = 0.0545, p = 0.0545

    There was also no significant difference between percentage changes of groups in creatinine concentration values after 3 years of the study (4.05 (-2.19 to 17.32%) vs -8.08 (-13.58 to -5.26%), p = 0.0545) (Table 4).

    PMID 39805983 · one of two readings recorded this

  • mouthfeel aversiveness, 0-100mm VAS

    no effect

    There were no statistically significant differences in mouthfeel between the samples in pairwise comparisons, while for smell, only the menthol/lemon-flavored 20-mg/mL oral solution (sample 447) had a less aversive smell than the unflavored compounded suspension (p = 0.003).

    PMID 41927994 · one of two readings recorded this

  • overall acceptability, 5-point facial hedonic scale

    decreases, compounded suspension significantly less acceptable than all other samples, p<0.001, n = 30

    This sample was significantly less acceptable than all other samples (p < 0.001), highlighting the distinct poor palatability profile.

    PMID 41927994 · both readings recorded this

  • taste and aftertaste aversiveness, 0-100mm VAS

    increases, compounded suspension significantly more aversive taste and aftertaste than all licensed formulations, p<0.001, n = 30

    Overall, the compounded 8.4% sodium bicarbonate suspension (sample 382) had a significantly more aversive, unpleasant taste and aftertaste than all the licensed omeprazole formulations (p < 0.001).

    PMID 41927994 · one of two readings recorded this

  • taste and aftertaste aversiveness, 100 mm visual analog scale (VAS)

    increases, n = 30

    Overall, the compounded 8.4% sodium bicarbonate suspension (sample 382) had a significantly more aversive, unpleasant taste and aftertaste than all the licensed omeprazole formulations (p < 0.001).

    PMID 41927994 · one of two readings recorded this

  • taste and aftertaste aversiveness of omeprazole liquid formulations, 100 mm visual analog scale (VAS)

    increases, n = 30

    Not recorded as a finding: this platform holds no node for the endpoint

    Overall, the compounded 8.4% sodium bicarbonate suspension (sample 382) had a significantly more aversive, unpleasant taste and aftertaste than all the licensed omeprazole formulations (p < 0.001).

    PMID 41927994 · one of two readings recorded this

  • taste and aftertaste aversiveness on a visual analog scale, and overall acceptability on a 5-point facial hedonic scale

    increases, compounded 8.4% sodium bicarbonate suspension significantly more aversive in taste and aftertaste than all licensed omeprazole formulations, p<0.001, n = 30

    Not recorded as a finding: this platform holds no node for the endpoint

    Overall, the compounded 8.4% sodium bicarbonate suspension (sample 382) had a significantly more aversive, unpleasant taste and aftertaste than all the licensed omeprazole formulations (p < 0.001).

    PMID 41927994 · one of two readings recorded this

  • 24-hour gastric pH > 6, percentage of time

    median 56.3% (IQR 28.0-92.0%) oral omeprazole vs 27.3% (IQR 4.4-77.7%) IV pantoprazole, p = 0.064, n = 124

    The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064).

    PMID 42438169 · one of two readings recorded this

  • 30-day rebleeding

    no effect, 3.3% vs 4.8%; risk difference -1.5%, 95% CI -10.1% to 7.0%, n = 124

    Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%).

    PMID 42438169 · one of two readings recorded this

  • 72-hour rebleeding requiring endoscopic hemostasis

    1.6% (1/61) omeprazole vs 4.8% (3/63) pantoprazole; risk difference -3.1%, 95% CI -11.6% to 4.6%, n = 124

    Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%).

    PMID 42438169 · one of two readings recorded this

  • percentage of 24-hour gastric pH above 6

    median 56.3% (IQR 28.0-92.0%) oral omeprazole vs 27.3% (IQR 4.4-77.7%) IV pantoprazole, p = 0.064

    The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064).

    PMID 42438169 · one of two readings recorded this

  • rebleeding at 72 hours and 30 days after therapeutic hemostatic endoscopy; 24-hour percentage of time gastric pH > 6

    no effect, 3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%, n = 124

    Not recorded as a finding: the comparison was against another active treatment

    Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%).

    PMID 42438169 · one of two readings recorded this

  • rebleeding at 72 hours requiring endoscopic hemostasis

    1.6% (1/61) oral omeprazole vs 4.8% (3/63) IV pantoprazole, risk difference -3.1%, 95% CI -11.6% to 4.6%, n = 124

    Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%).

    PMID 42438169 · one of two readings recorded this

  • rebleeding within 30 days

    no effect, 3.3% vs 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%, n = 124

    Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%).

    PMID 42438169 · one of two readings recorded this

  • Cmax and AUC0-t intra-subject variability, fed conditions

    CV Cmax 46.79%, CV AUC0-t 31.61%

    Under fed conditions, high intra-subject variability was observed for Cmax (CV = 46.79%) and AUC0-t (CV = 31.61%).

    PMID 42665804 · one of two readings recorded this

  • Cmax, AUC0-t, AUC0-∞ bioequivalence, fasting conditions

    GMR Cmax 101.33%, AUC0-t 101.81%, AUC0-∞ 101.76%; all 90% CIs within 80.00-125.00%

    In the fasting study, the geometric mean ratios (GMRs) of Cmax, AUC0-t, and AUC0-∞ were 101.33%, 101.81%, and 101.76%, respectively, with all 90% confidence intervals (CIs) falling within the bioequivalence range of 80.00-125.00%.

    PMID 42665804 · one of two readings recorded this

  • direct medical healthcare cost per patient (provider and patient perspective)

    decreases, n = 20

    From the provider perspective, omeprazole plus standard treatment reduced healthcare costs by 4642.30 Baht per patient compared with standard treatment alone.

    PMID 42736784 · one of two readings recorded this

  • incremental cost-effectiveness ratio (healthcare cost per stricture prevented)

    decreases, n = 20

    From the provider perspective, omeprazole plus standard treatment reduced healthcare costs by 4642.30 Baht per patient compared with standard treatment alone.

    PMID 42736784 · one of two readings recorded this